Massarweh A, Eliakim-Raz N, Stemmer A, et al. - Cancer patients should receive vaccination against SARS-CoV-2 infection as a high priority, even during therapy as 90% of cancer patients undergoing active systemic therapy demonstrated adequate antibody response to the BNT162b2 vaccine, though they had significantly lower antibody titers than healthy controls.

• Cancer patients on treatment are at high risk of COVID-19 after SARS-CoV-2 infection.

• This prospective cohort study included 180 participants; 102 were cancer patients and 78 were healthy controls.

• The most common tumor type was gastrointestinal (29 [28%]).

• Following the second messenger RNA BNT162b2 vaccine dose, seropositivity was evident in 92 patients with cancer (90%) and 100% of the controls.

• Significantly lower median IgG titer was found in cancer patients vs controls.

• Multivariable analysis revealed that treatment with chemotherapy plus immunotherapy was the only variable significantly linked with lower IgG titers.